Pilar G.
- Country
- Spain
- Department
- Oncology
Research Overview
- Evaluation of ASP3082 in Adult Patients with Advanced Solid Tumors
- Evaluation of STX-721 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Specific Mutations
- Efficacy of Cobolimab, Dostarlimab, and Docetaxel in Advanced Non-Small Cell Lung Cancer Post Anti-PD(L)1 Therapy and Chemotherapy
Data & Insights
Has run more than one trial at 355 of 583 partner sites.
Specializations
Advanced Lung Cancer
The investigator specializes in treating non-small cell lung cancer (NSCLC), with particular focus on cases involving specific genetic mutations including HER2 (ERBB2), RAS G12C, and EGFR Exon20 insertions.
- Mutation-targeted therapies
- Advanced stage treatment approaches
- Personalized medicine strategies
Expertise extends to both squamous and non-squamous NSCLC variants, particularly in metastatic disease settings.
Immunotherapy Applications
Demonstrates significant involvement in immunotherapy-based treatments, particularly focusing on pembrolizumab combinations and novel immune checkpoint inhibitor approaches for lung cancer.
- Combination immunotherapy protocols
- Anti-PD(L)1 therapy
- Novel immunotherapy agents
Active investigation of immune-based therapeutic strategies for treatment-resistant cases.
Precision Oncology
Explores targeted therapeutic approaches for specific genetic mutations in cancer treatment, including evaluation of novel compounds and combination strategies.
- Molecular targeting agents
- Biomarker-driven treatments
- Combination therapy development
Focuses on developing personalized treatment strategies based on specific genetic profiles.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.